Redhill Biopharma Ltd.

RedHill Biopharma Ltd. focuses on gastrointestinal and infectious diseases. They develop and commercialize Talicia for H. pylori infection and Aemcolo for travelers diarrhea. Their pipeline includes five therapeutic candidates: opaganib, RHB-107, RHB-104, RHB-102, and RHB-204. These candidates are in clinical development for various indications. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Overview

Sector

Pharmaceutical

Target Price

0.0 USD

Current Price

1.5 USD

Potential

-100%

Strengths

The company has low debt. Net Debt to EBITDA Ratio is 0.32 and it is lower than the sector mean.
The company has high returns. ROIC (100.00%) is higher than the sector mean (14.71%).

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
EV/EBITDA (100.00) is significantly higher than the sector mean (51.86).
The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
EBITDA Margin (0.00%) appears relatively low.

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	100.0%
Net Debt/EBITDA	0.3

Redhill Biopharma Ltd.

Overview

Strengths

Weaknesses

Key Financial Data